Navigation Links
Edwards' Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg
Date:10/23/2007

- Arterial Blockages in the Leg are Estimated to Affect 8 Million Americans

-

WASHINGTON, Oct. 23 /PRNewswire-FirstCall/ -- Edwards Lifesciences Corporation (NYSE: EW), a world leader in products and technologies to treat advanced cardiovascular disease, today announced the 12-month results from The RESILIENT Trial, presented as the "Blockbuster" Trial of the Day at the Cardiovascular Research Foundation's 19th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C. The landmark trial demonstrates statistically superior results using the LifeStent self-expanding stent versus balloon angioplasty alone in treating peripheral arterial disease (PAD) in the superficial femoral artery (SFA) and proximal popliteal artery. These arteries are the major circulatory channels for the upper leg and knee.

"The RESILIENT Trial is a randomized, multi-center study using the flexible LifeStent self-expanding stent in the understudied and challenging SFA region," said Barry T. Katzen, M.D., Founder and Medical Director of Baptist Cardiac and Vascular Institute, and co-principal investigator for The RESILIENT Trial. "The results of this trial show the statistical superiority of the LifeStent self-expanding stent versus balloon angioplasty alone as the need for follow-up intervention was 13% versus 54%, respectively, at 12 months."

The RESILIENT Trial further demonstrated the SFA patency rate, or percentage of vessels with unobstructed blood flow, was 80% for patients who received the LifeStent self-expanding stent versus 38% for patients with balloon angioplasty alone.

"Results from The RESILIENT Trial are expected to establish the LifeStent
'/>"/>

SOURCE Edwards Lifesciences Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
7. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
8. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
9. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014  Tasly Pharmaceuticals, Inc., the world,s leader ... today the launch of Deepure. Deepure ... men and women concerned with supporting their overall ... age while helping keep their health care cost ... herb-based formulas, namely, ProHeart PLUS, ImmunoPower PLUS, and ...
(Date:9/30/2014)... 30, 2014 Aileron Therapeutics, Inc. - ... Global Markets Direct,s, ,Aileron Therapeutics, Inc. - Product ... the Aileron Therapeutics, Inc.,s pharmaceutical research and development ... the current therapeutic developmental pipeline of Aileron Therapeutics, ... therapeutics assessment by drug target, mechanism of action ...
(Date:9/30/2014)... 2014 According to ... by Product [Enzymes (Glycosyltransferase, Neuraminidase, Glycosidase), Instruments ... Application (Immunology, Oncology) & by End User ... MarketsandMarkets, provides a detailed overview of the ... trends, and strategies impacting the global glycomics ...
Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
... 9 Peptimmune, Inc., a privately,held biotechnology ... peptide copolymer program at both the 17th ... FOCIS 2008 in Boston, MA. The Company ... study involving,healthy, male adult volunteers following SC ...
... juice has ... NEW YORK, June 9 CherryPharm -- a proprietary,all-natural ... of,cherries -- has been shown to improve aspects of sleep, ... This double-blind,placebo controlled clinical trial tested the effectiveness of CherryPharm,in ...
Cached Medicine Technology:Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings 2Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings 3CherryPharm First All-Natural Food to Improve Sleep 2
(Date:10/2/2014)... -- Genes may interact with stress to trigger heart disease ... risk occurs in about 13 percent of people, but only ... people reduce their heart disease risk through simple measures such ... Duke University researchers said. The study authors analyzed genetic ... between variations in the EBF1 gene and higher levels of ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, ... roses -- literally -- may face an increased risk of dying ... study of over 3,000 older Americans, researchers found those who were ... more than three times as likely to die in the next ... In fact, anosmia -- the inability to distinguish odors -- was ...
(Date:10/1/2014)... developed a model that could help to predict a ... from their very first psychotic episode. , The model ... symptoms, cognitive abilities, MRI scans of the brain,s structure, ... the lead up to World Mental Health Day (10 ... Professor Bernhard Baune , says the model is a ...
(Date:10/1/2014)... the human eye, the brain of a rat and ... technology, says a QUT leading robotics researcher. , ... says the new study uses new computer algorithms to ... or tunnels. , "This is a very Frankenstein type ... halves of a thing together because we,re taking the ...
(Date:10/1/2014)... encourages people to keep their "eyes on the prize" ... When walking, staying focused on a specific target ahead ... help people walk there faster, psychology researchers have found. ... looking around the environment naturally, offers a new strategy ... less interested in exercise if physical activity seems daunting, ...
Breaking Medicine News(10 mins):Health News:Genes May Make Some More Prone to Heart Disease When Under Stress 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3Health News:Predicting the future course of psychotic illness 2Health News:Robot researcher combines nature to nurture 'superhuman' navigation 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3
... suffered cardiac death would have their bodies prepared for ... Australian Health Ethics Committee that is working on organ ... patients who are certain to die after experiencing cardiac ... heart, liver lungs and kidneys begin to deteriorate immediately ...
... help Alzheimer's patients interact and communicate with others, finds ... Newcastle General Hospital studied the benefits of dolls after ... from her son, reported the online edition of BBC ... can lose their intellectual, social and emotional abilities over ...
... major public health threat posed by antibiotic-resistant bacteria, ... (UCSD) are launching a new program to develop ... and testing, to clinical trials. ,"UCSD ... necessary expertise to fight this urgent medical problem," ...
... discovered around 1994 which has the ability to perform multi ... other crucial physiological activities. , But the ... out these metabolic activities were not known till date. Now, ... University have identifies the mode in which Leptin carries out ...
... University, Doug Goodin, makes use of satellite imagery to ... //changes on human health and food security. ... types of data, to monitor and predict the spread ... discussed this subject at the workshop, "Contributions of Remote ...
... men for a good 14 years has revealed that regular ... body weight has an impact in cutting down the risks ... co-author of the study, said "Even though erectile problems were ... clear that heart disease and ED share many of the ...
Cached Medicine News:Health News:New UCSD Program to Fight Drug-Resistant Bacteria 2Health News:New UCSD Program to Fight Drug-Resistant Bacteria 3Health News:New UCSD Program to Fight Drug-Resistant Bacteria 4Health News:How Does Leptin Work? 2Health News:Satellite Imagery to monitor the Social Impact Of Geographical Changes 2
... Disease ELISA kits utilize ... Also included in each ... negative controls, serum diluent, ... Use an ELISA plate ...
... (PCR) technology, the worlds leading nucleic acid ... Roches blood screening assays and other diagnostic ... unique regions of genetic material to be ... to detectable levels) in only a few ...
... Continuing to lead the market in ... WAVE IABP is a whole new first ... optic technology coupled with a physiologically based ... support with unprecedented timing accuracy. Second ...
... worlds first truly automated immunohistochemistry ... a whole new level of ... modularity and ease of operation ... NexES Systems automated technology provides ...
Medicine Products: